Semin Thromb Hemost 2011; 37(6): 713-720
DOI: 10.1055/s-0031-1291382
© Thieme Medical Publishers

Quebec Platelet Disorder: Update on Pathogenesis, Diagnosis, and Treatment

Jessica Blavignac1 , Natalia Bunimov1 , Georges E. Rivard2 , Catherine P.M. Hayward1
  • 1Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario
  • 2Service d'hématologie-oncologie, CHU Sainte-Justine, Montréal, Québec, Canada
Further Information

Publication History

Publication Date:
18 November 2011 (online)


Quebec platelet disorder (QPD) is an autosomal dominant bleeding disorder associated with reduced platelet counts and a unique gain-of-function defect in fibrinolysis due to increased expression and storage of urokinase plasminogen activator (uPA) by megakaryocytes. QPD increases risks for bleeding and its key clinical feature is delayed-onset bleeding, following surgery, dental procedures or trauma, which responds only to treatment with fibrinolytic inhibitors. The genetic cause of the disorder is a tandem duplication mutation of the uPA gene, PLAU, which upregulates uPA expression in megakaryocytes by an unknown mechanism. The increased platelet stores of uPA trigger plasmin-mediated degradation of QPD α-granule proteins. The gain-of-function defect in fibrinolysis is thought to be central to the pathogenesis of QPD bleeding as the activation of QPD platelets leads to release of uPA from α-granules and accelerated clot lysis. The purpose of this review is to summarize current knowledge on QPD pathogenesis and the recommended approaches to QPD diagnosis and treatment.


  • 1 Diamandis M, Veljkovic D K, Maurer-Spurej E, Rivard G E, Hayward C P. Quebec platelet disorder: features, pathogenesis and treatment.  Blood Coagul Fibrinolysis. 2008;  19 (2) 109-119
  • 2 Veljkovic D K, Rivard G E, Diamandis M, Blavignac J, Cramer-Bordé E M, Hayward C P. Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation.  Blood. 2009;  113 (7) 1535-1542
  • 3 Diamandis M, Paterson A D, Rommens J M et al.. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes.  Blood. 2009;  113 (7) 1543-1546
  • 4 Kahr W H, Zheng S, Sheth P M et al.. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator.  Blood. 2001;  98 (2) 257-265
  • 5 Diamandis M, Adam F, Kahr W H et al.. Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis.  J Thromb Haemost. 2006;  4 (5) 1086-1094
  • 6 Diamandis M, Veljkovic D K, Derome F, Rivard G E, Hayward C P. Evaluation of urokinase plasminogen activator in urine from individuals with Quebec platelet disorder.  Blood Coagul Fibrinolysis. 2008;  19 (5) 463-464
  • 7 Paterson A D, Rommens J M, Bharaj B et al.. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene.  Blood. 2010;  115 (6) 1264-1266
  • 8 Tracy P B, Giles A R, Mann K G, Eide L L, Hoogendoorn H, Rivard G E. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.  J Clin Invest. 1984;  74 (4) 1221-1228
  • 9 Hayward C P, Rivard G E, Kane W H et al.. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect.  Blood. 1996;  87 (12) 4967-4978
  • 10 Hayward C P, Cramer E M, Kane W H et al.. Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules.  Blood. 1997;  89 (4) 1243-1253
  • 11 Janeway C M, Rivard G E, Tracy P B, Mann K G. Factor V Quebec revisited.  Blood. 1996;  87 (9) 3571-3578
  • 12 Hayward C P, Welch B, Bouchard M, Zheng S, Rivard G E. Fibrinogen degradation products in patients with the Quebec platelet disorder.  Br J Haematol. 1997;  97 (2) 497-503
  • 13 McKay H, Derome F, Haq M A et al.. Bleeding risks associated with inheritance of the Quebec platelet disorder.  Blood. 2004;  104 (1) 159-165
  • 14 Hayward C P, Rivard G E. Quebec platelet disorder.  Expert Rev Hematol. 2011;  4 (2) 137-141
  • 15 Homo Sapiens Chromosome 10. NCBI Map Viewer Website: Homo sapiens (human) genome view Build 36 6 statistics 2009. Accessed October 10, 2010; 
  • 16 Abbasi A H, Shaikh Q, Hussain S A. Quebec platelet disorder.  J Coll Physicians Surg Pak. 2010;  20 (8) 549-550
  • 17 Sheth P M, Kahr W H, Haq M A, Veljkovic D K, Rivard G E, Hayward C P. Intracellular activation of the fibrinolytic cascade in the Quebec platelet disorder.  Thromb Haemost. 2003;  90 (2) 293-298
  • 18 Kufrin D, Eslin D E, Bdeir K et al.. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets.  Blood. 2003;  102 (3) 926-933
  • 19 Heckel J L, Sandgren E P, Degen J L, Palmiter R D, Brinster R L. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator.  Cell. 1990;  62 (3) 447-456
  • 20 Weiss H J, Lages B, Zheng S, Hayward C P. Platelet factor V New York: a defect in factor V distinct from that in factor V Quebec resulting in impaired prothrombinase generation.  Am J Hematol. 2001;  66 (2) 130-139

Catherine P.M. Hayward, M.D. , Ph.D. , F.R.C.P. (C) 

Department of Pathology and Molecular Medicine, McMaster University

2N29A, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada